Short Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Declines By 85.5%

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,000 shares, a drop of 85.5% from the January 15th total of 13,800 shares. Based on an average daily volume of 57,000 shares, the short-interest ratio is presently 0.0 days.

Appili Therapeutics Stock Performance

Shares of Appili Therapeutics stock remained flat at $0.02 on Wednesday. Appili Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.05. The stock has a market cap of $2.83 million, a P/E ratio of -1.17 and a beta of -0.53. The firm has a 50-day moving average of $0.02 and a 200 day moving average of $0.03.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.